470 related articles for article (PubMed ID: 34276675)
1. T-Cell Mediated Inflammation in Postmenopausal Osteoporosis.
Wu D; Cline-Smith A; Shashkova E; Perla A; Katyal A; Aurora R
Front Immunol; 2021; 12():687551. PubMed ID: 34276675
[TBL] [Abstract][Full Text] [Related]
2. Postmenopausal osteoporosis: the role of immune system cells.
Faienza MF; Ventura A; Marzano F; Cavallo L
Clin Dev Immunol; 2013; 2013():575936. PubMed ID: 23762093
[TBL] [Abstract][Full Text] [Related]
3. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis.
Lyritis GP; Georgoulas T; Zafeiris CP
Ann N Y Acad Sci; 2010 Sep; 1205():277-83. PubMed ID: 20840284
[TBL] [Abstract][Full Text] [Related]
4. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
5. Estrogen deficiency, T cells and bone loss.
Pacifici R
Cell Immunol; 2008; 252(1-2):68-80. PubMed ID: 17888417
[TBL] [Abstract][Full Text] [Related]
6. Anabolic agents: a new chapter in the management of osteoporosis.
Khan AW; Khan A
J Obstet Gynaecol Can; 2006 Feb; 28(2):136-41. PubMed ID: 16643716
[TBL] [Abstract][Full Text] [Related]
7. Experimental techniques for screening of antiosteoporotic activity in postmenopausal osteoporosis.
Satpathy S; Patra A; Ahirwar B
J Complement Integr Med; 2015 Dec; 12(4):251-66. PubMed ID: 26215536
[TBL] [Abstract][Full Text] [Related]
8. Are Oxidative Stress and Inflammation Mediators of Bone Loss Due to Estrogen Deficiency? A Review of Current Evidence.
Mohamad NV; Ima-Nirwana S; Chin KY
Endocr Metab Immune Disord Drug Targets; 2020; 20(9):1478-1487. PubMed ID: 32496996
[TBL] [Abstract][Full Text] [Related]
9. Interaction between bone and immune cells: Implications for postmenopausal osteoporosis.
Fischer V; Haffner-Luntzer M
Semin Cell Dev Biol; 2022 Mar; 123():14-21. PubMed ID: 34024716
[TBL] [Abstract][Full Text] [Related]
10. Combination anabolic and antiresorptive therapy for osteoporosis.
Cusano NE; Bilezikian JP
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):643-54. PubMed ID: 22877434
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 27 (IL-27) Alleviates Bone Loss in Estrogen-deficient Conditions by Induction of Early Growth Response-2 Gene.
Shukla P; Mansoori MN; Kakaji M; Shukla M; Gupta SK; Singh D
J Biol Chem; 2017 Mar; 292(11):4686-4699. PubMed ID: 28130449
[TBL] [Abstract][Full Text] [Related]
12. T cells and post menopausal osteoporosis in murine models.
Pacifici R
Arthritis Res Ther; 2007; 9(2):102. PubMed ID: 17349065
[TBL] [Abstract][Full Text] [Related]
13. Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis.
Papapoulos S; Makras P
Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):514-23. PubMed ID: 18714329
[TBL] [Abstract][Full Text] [Related]
14. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial.
Lambert MNT; Thybo CB; Lykkeboe S; Rasmussen LM; Frette X; Christensen LP; Jeppesen PB
Am J Clin Nutr; 2017 Sep; 106(3):909-920. PubMed ID: 28768651
[No Abstract] [Full Text] [Related]
15. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
Dalle Carbonare L; Arlot ME; Chavassieux PM; Roux JP; Portero NR; Meunier PJ
J Bone Miner Res; 2001 Jan; 16(1):97-103. PubMed ID: 11149495
[TBL] [Abstract][Full Text] [Related]
16. Perspectives in the treatment and prevention of osteoporosis.
Gennari L; Merlotti D; Nuti R
Drugs Today (Barc); 2009 Aug; 45(8):629-47. PubMed ID: 19927228
[TBL] [Abstract][Full Text] [Related]
17. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
18. One year in review 2018: progress in osteoporosis treatment.
Figliomeni A; Signorini V; Mazzantini M
Clin Exp Rheumatol; 2018; 36(6):948-958. PubMed ID: 30526765
[TBL] [Abstract][Full Text] [Related]
19. Denosumab for postmenopausal osteoporosis?
Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
[TBL] [Abstract][Full Text] [Related]
20. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
